Clinical Research · us
Delivering an Immunotoxin Into Brain Tumors: 81-Patient Trial Establishes Recommended Dose and Investigates Survival Differences
A phase 1 trial in recurrent malignant glioma identified an administration concentration for further studies of an EGFR-targeted immunotoxin and yielded clues linking immune responses with survival. Whether it can extend life remains a question for controlled trials.
For recurrent malignant glioma, treatment research must answer two questions at once: how to deliver the drug to the tumor, and whether patients can tolerate it. An 81-patient phase 1 trial published in Nature Medicine on October 16 used direct infusion of an immunotoxin into brain tumors to establish a recommended dose for further studies and explore which biological features were associated with longer survival.
The drug, D2C7-ATC, combines an antibody with a toxin and recognizes epidermal growth factor receptor EGFR and its mutant form, EGFRvIII. The study used “convection-enhanced delivery” to administer the drug into tumors through a catheter. CenterWatch lists the same trial, NCT02303678, under the drug name D2C7-IT; patients first had to have recurrence confirmed by biopsy, then receive a continuous 72-hour intratumoral infusion during hospitalization.
The trial was conducted at a single center at Duke University, with no control group. Its primary objectives were to assess toxicity and identify a recommended phase 2 dose. The team ultimately selected an infusion concentration of 6,920 nanograms per milliliter. The formal journal abstract states that at the highest concentration tested, 35,032 nanograms per milliliter, four patients experienced dose-limiting toxicities, including two grade 4 and two grade 3 events, indicating that local administration still has clear safety limits.
The survival results require a clear distinction between the populations analyzed. The formal paper abstract reports that among the 81 participants, the 72 patients with IDH-wildtype recurrent glioblastoma had a median overall survival of 7.9 months. This was an observation following treatment; without a concurrent control group, it cannot establish that the drug prolonged survival, nor can it be used to directly compare efficacy with other trials.
To understand differences among patients, the team also analyzed signals in tumors and blood. The summary for dataset GSE327275, indexed in OmicsDI, states that 27 patients with available tumor and plasma samples underwent exploratory analysis. The formal journal abstract lists several clues associated with survival, including tumor reactivity to the D2C7 antibody, inflammation-related gene expression, immune cells in the blood, and the cytokine IL-8 in plasma after treatment.
However, the dataset summary and the formally published version are not entirely consistent: the former names IL-18, while the latter names IL-8, and the numbers of patients with dose-limiting toxicities also differ. Specific results should therefore follow the formal journal version, and figures from the two abstracts should not be mixed. These biomarkers come from exploratory univariate analyses and have not yet been shown to be useful for selecting patients or predicting an individual's treatment outcome.
This study provides a concentration for use in subsequent trials and directions for further investigation of immune responses. The key next step is to confirm the benefits and risks of local infusion in larger studies with appropriate controls, and to clarify whether the signals associated with survival reflect patients' underlying disease characteristics or are related to the treatment's effects.